Effects of endothelial cells on activity of staphylokinase.
Staphylokinase (SAK), produced by Staphylococcus aureus, induces fibrinolytic activity in circulation without systemic fibrinolytic activation. Since the effect of blood vessels on the activity of SAK has not yet been clarified, plasminogen activator (PA) activity of SAK in the presence or absence of endothelial cells was analyzed. The endothelial cells used in this experiment were of a cloned established cell line (TKM-33). In the expression of PA activity by SAK or streptokinase (SK), the kinetic constants revealed as Vmax/km were increased about 1.5-fold in the presence of endothelial cells. Furthermore, an initial lag phase which was observed during the plasminogen activation by SAK was markedly shortened in the presence of endothelial cells. In the case of SK, an initial lag phase was not observed in the absence or presence of endothelial cells. Although PA activity of SAK was inhibited by alpha 2-antiplasmin (alpha 2-AP), the inhibitory effect of alpha 2-AP in the presence of endothelial cells was weaker than in the absence of endothelial cells. The cyanogen bromide digested fibrinogen fragment-2 (FCB-2) distinctly enhanced the PA activity of SAK in the absence and the presence of endothelial cells. However, alpha 2-AP and FCB-2 did not cause a significant alteration of PA activity of SK even in the absence or presence of endothelial cells. These findings suggest that PA activity of SAK is enhanced by endothelial cells, but inhibited by alpha 2-AP. Moreover, PA activity of SAK is further enhanced by fibrin clot in the presence of endothelial cells.
Ueshima
S
S
Department of Physiology, Kinki University School of Medicine, Osaka, Japan.
Okada
K
K
Matsumoto
H
H
Takaishi
T
T
Fukao
H
H
Matsuo
O
O
D002460:Cell Line; D004730:Endothelium, Vascular / Q000502:physiology*; D004789:Enzyme Activation / Q000187:drug effects; D005338:Fibrin Fibrinogen Degradation Products / Q000494:pharmacology; D005341:Fibrinolysin / Q000096:biosynthesis; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008666:Metalloendopeptidases / Q000494:pharmacology*; D009842:Oligopeptides / Q000378:metabolism; D010958:Plasminogen / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D000979:alpha-2-Antiplasmin / Q000494:pharmacology
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D009842:Oligopeptides; D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; C018788:valyl-leucyl-lysine 4-nitroanilide; D010958:Plasminogen; D005341:Fibrinolysin; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus